AI Can Identify Blood-Based Markers Of Alzheimer’s For Earlier Diagnosis & Tracking

Artificial intelligence (AI) can identify blood-based biomarkers of Alzheimer’s disease. The technology was used to analyze a variety of medical data—structural brain imaging, genetics, plasma, and cerebrospinal fluid (CSF) markers—of cognitively normal individuals, those with mild cognitive impairment, and those with Alzheimer’s disease. The analysis revealed risk factors that were aligned with established biological pathways in Alzheimer’s disease. These factors were able to improve disease prediction along the trajectory from normal cognition and mild cognitive impairment to Alzheimer’s disease, with prediction accuracy of 89.9%.

These findings were reported in “Uncovering Biologically Coherent . . .